A High Cost for Health | GenomeWeb

Insurance companies and drugmakers are wrestling with the high cost of making and administering biologic drugs, says Avery Johnson on the Wall Street Journal's Health blog. These drugs can cost as much as $1.5 million a year, and patients and prescription plan payers are having a hard time affording them. On the other hand, Johnson adds, some of these drugs have "dramatic" results, sending sometimes-fatal diseases into remission.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.